Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
camizestrant + capivasertib
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Camizestrant (AZD9833) is an oral selective estrogen receptor degrader (SERD) developed to inhibit estrogen receptor signaling in hormone receptor-positive breast cancer. It works by binding to and degrading the estrogen receptor, thereby blocking the growth-promoting effects of estrogen on breast cancer cells[3][8]. Capivasertib (AZD5363, brand name Truqap) is a small molecule inhibitor of all three isoforms of AKT serine/threonine kinase (AKT1, AKT2, AKT3), a key component in the PI3K/AKT pathway frequently altered in breast cancer. By inhibiting AKT activity, capivasertib disrupts downstream signaling that promotes tumor cell survival and proliferation[1][5][6]. The combination of camizestrant and capivasertib is being investigated for advanced or metastatic hormone receptor-positive/HER2-negative breast cancer with specific genetic alterations such as PIK3CA mutations or PTEN loss[1][5].
- Other names
- AZD9833 + capivasertibAZD9833 + AZD5363camizestrant + capivasertib
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AKT2 (Rac-beta serine/threonine-protein kinase)AKT3 (RAC-gamma serine/threonine-protein kinase)ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on camizestrant + capivasertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on camizestrant + capivasertib.